NDC 72988-0012-01: Yobisin rehmannia root, angelica gigas root 16.7 mg; 416.7 mg; 416.7 mg; 416.7 mg; 250 mg; 125 mg; 250 mg; 16.7 mg Tablet, 20-count
This is a package of 20 tablets of Yobisin rehmannia root, angelica gigas root 16.7 mg; 416.7 mg; 416.7 mg; 416.7 mg; 250 mg; 125 mg; 250 mg; 16.7 mg Tablet from Lydia Co., Ltd., first listed with the FDA Apr 2019 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 72988-0012-1 alone.
- Record
- FDA NDC Directory package listing · Human OTC drug
- Code segments
- 72988 labeler · 0012 product · 1 package
- Package marketed since
- Apr 24, 2019
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 7298800121 9
- FDA record last changed
- Nov 19, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
YOBISIN is an oral tablet containing a blend of plant-derived ingredients that are commonly used in traditional herbal formulations. The formula includes rehmannia root, angelica gigas root, and other botanicals such as ginger, licorice, forsythia fruit, rhubarb, and scutellaria root, along with several additional plant materials. These ingredients are traditionally associated with supporting digestive and inflammatory responses, though this product is marketed without FDA approval and its safety and effectiveness have not been established through standard regulatory review.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 72988-0012-01 You're viewing this Main listing | 20 TABLET in 1 PACKAGE | 2019-04-24 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Yobisin 16.7 mg/1; 416.7 mg/1; 416.7 mg/1; 416.7 mg/1; 250 mg/1; 125 mg/1; 250 mg/1; 16.7 mgthis 72988-0012-01 | Lydia | 20 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
1 inactive ingredient listed in the exact product block matched to this NDC.
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Lydia Co., Ltd. labeler code 72988
- MOSQUITO BUG OFF DIETHYLTOLUAMIDE 10 g/100mL Liquid NDC 72988-0005-1
- Hot Pap Cataplasma Methyl salicylate, vanillyl nonylamide 58.3 mg/13.4g; 5 mg/13.4g Patch NDC 72988-0007-1
- Laxatives Rubilax psyllium huskpowder 2168 mg/3.5g; 496 mg/3.5g Granule NDC 72988-0010-2
- Baenosin platycodon root, licorice, jujube, peony root .5 g; .5 g; .67 g; .5 g; .5 g; .5 g Capsule NDC 72988-0011-1
- Co Cool menthol, peppermint oil, pinus pumilio branch/leaf oil .06 g/100g; .01 g/100g; .01 g/100g Liquid NDC 72988-0013-1
- AMULDY SPORTS gel menthol, methyl salicylate, camphor, salicylic acid .3 g/100mL; 2.5 g/100mL; .03 g/100mL; .05 g/100mL Liquid NDC 72988-0023-1
- NOCOLD-F ACETAMINOPHENE. CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE 200 mg/30mL; 15 mg/30mL; 2.5 mg/30mL Liquid NDC 72988-0027-1
- ANTIPHLAMINE L-Menthol, L-Camphor, Methyl Salicylate 59 mg/g; 8 mg/g; 46 mg/g Lotion NDC 72988-0028-1
- CHUNGWIDAN-F cinnamon, nutmeg 500 mg/30mL; 300 mg/30mL Liquid NDC 72988-0029-1
- Metarivin Soln. 0.1% Xylometazoline Hydrochloride 1 mg/mL Liquid NDC 72988-0030-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
FDA label — Drug Facts FDA SPL
🎯 Indications and Usage ▾
adults: 3~6 tablets twice a day 7 to 14 years old: 2-3 tablets twice a day
⏱️ Dosage and Administration ▾
for oral use only
⚠️ Warnings ▾
do not take this medicine if you have following symptoms children under 6 years old women who are likely to be pregnant or pregnant breastfeeding
🧪 Active Ingredient ▾
rehmannia root, angelica gigas root, akebia stem, scutellaria root, alisma rhizome, plantago seed, licorice, gardenia fruit, gentian root and rhizome, cinnamomum cassia presl, raw ginger, rhubarb, ephdra heab, forsythia fruit
🧪 Inactive Ingredients ▾
magnesium stearate, corn starch, polyethylene glycol 6000, hypromellose 2910
🎯 Purpose ▾
bladder qatar, urethritis, kidney disease, nephrotic syndrome, edema
📄 Keep Out of Reach of Children ▾
keep out of reach of the children
📄 Package Label / Principal Display Panel ▾
label
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |